slides · global inventory
Sequoia Pitch
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 43,093
Current window 26,281-26,310
Pages 1,437
Rows per page 30
Arc
26,281-26,310 of 43,093
26
The slide contrasts the massive combined market of established CPIs ($42B) with the smaller market share of Libtayo ($0.5B) to frame the opportunity for partnership/growth.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
27
The slide uses market cap data to establish valuation benchmarks and cites recent M&A activity as a validation of the sector's value.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Competition1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection to diagnostic output.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a visual timeline/process flow to show disease progression.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
15
The slide uses two scatter plots to benchmark the company against competitors like Guardant Health, CellMax Life, and Cologuard.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market Size1 hit
19
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Team1 hit
20
The slide uses a grid layout to present 10 advisors, each with a headshot, name, role, and company logo.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Team1 hit
05
Uses a before-after-bridge style framing to connect pain points to product benefits.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The central hub is 'Accelerate Product Development', surrounded by four strategic pillars, each with a corresponding icon.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The slide uses a process flow diagram to show the funnel from potential partnerships to active clinical programs.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
08
The chart shows a cumulative growth trend of partner milestones over time, with logos placed in vertical columns representing years.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
09
Uses a stacked area chart to represent revenue components (instruments, milestones, sales-based payments) over time.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
10
The slide uses two donut charts to visualize the distribution of milestone events across IND, Pre-Pivotal, and Pivotal or Later phases.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
11
The chart uses a stacked bar format to distinguish between pre-commercial and commercial revenue components.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
The slide uses a wave-based metaphor to represent sequential growth phases of partner programs.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
The diagram uses concentric circles to represent clinical phases and color-coded dots for cell approaches (Allogeneic vs Autologous).MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
The slide uses a Vitruvian-man style silhouette to represent the breadth of therapeutic applications.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The model is explicitly labeled as 'Razor/Razor Blade Economics'.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · Business Model1 hit
17
Uses the 'Razor/Razor Blade' business model framework.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · Business Model1 hit
21
MaxCyte | Investor Presentation Deck | 21 slidesMaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · The AskLoop · Why Now1 hit
03
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Team1 hit
04
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
05
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
07
The slide uses a medical illustration of the liver to highlight the target organ.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide uses a standard comparison table format to contrast a competitor (Resmetirom) with the company's own asset (DA-1241).NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
09
The diagram shows a biological pathway from steatosis to steatohepatitis to fibrosis, highlighting the role of GPR119 activation in modulating cellular responses.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
10
The slide shows two heatmaps (17 inflammation genes, 22 stellate cell activation genes) and a biological pathway diagram.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
Includes specific study references and definitions for abbreviations like GPR119, MASH, and GLP-1.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
The slide presents 10 distinct bar charts comparing Control, DA, DA+DPP4i, and DPP4i groups, with statistical significance markers.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit